ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma is listed on Nasdaq Stockholm main market (small cap) under the ticker ACE

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• November 4 @ 14:10 - 14:40

  Stora Aktiedagen Göteborg

• November 8 @ 08:00

  Ascelia Pharma interim report Q1 (Jul-Sep 2019) for fiscal year 2019/2020

• November 14 @ 11:00 - 12:00

  Ascelia Pharma Annual General Meeting

• November 19

  Redeye Life Science Day

• 2019-10-14Notice of Annual General Meeting of Ascelia Pharma AB
• 2019-10-14Ascelia Pharma publishes Annual Report for the financial year 2018/2019
• 2019-09-11Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019
• 2019-09-06Ascelia Pharma to present at Share Day (Aktiedagen) in Stockholm on 10 September 2019
• 2019-08-22Full-year financial report 2018/2019: Phase III study of Mangoral to start in H2-2019